80 results on '"de Castro, J."'
Search Results
2. Prognostic Potential of Candidate miRNAs in Lung Cancer: Insights from Tissue and Liquid Biopsies
3. Glioma Patient Management: Utilizing MGMT Methylation in Extracellular Vesicle-Based Liquid Biopsy
4. EP.13A.05 Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
5. P1.13A.11 Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study.
6. P088 - Renal tumors with left renal vein tumoral thrombosis. Is Preoperative Renal Artery Embolization (PRAE) helpful?
7. Variation of quality of life in patients with obstructive sleep apnea hipopnea syndrome after treatment with mandibular advance device
8. P3.08E.04 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials.
9. P267 - Quality of life in patients with Non-Muscle Invasive Bladder Cancer (NMIBC) subjected to intravesical instillations with BCG induction
10. P037 - Risk of detecting prostate cancer based on the PSAD and PIRADS lesions in MRI in patients with a negative previous biopsy.
11. Study of the immunologic response of marine-derived collagen and gelatin extracts for tissue engineering applications.
12. P032 - Prostate rebiopsy in patients with a negative previous biopsy and MRI. When should it be done?
13. P013 - Age. An exponential risk factor for prostate cancer
14. EP15.03-04 Unscheduled Hospitalizations in Patients with Lung Cancer as a Frailty Event.
15. P2.14-01 Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC.
16. MA16.04 Circulating Tumor DNA Quantification by NGS Should Be Adapted to the Methodology Used.
17. P115 - Development of a predictive model for optimizing the selection of patients for second transurethral resection bladder (TURB)
18. P112 - Risk model- recurrence risk groups for patients with localised renal cell carcinoma
19. P026 - Oncological control in high-risk prostate cancer after radical prostatectomy and salvage radiotherapy compared to radiotherapy plus primary hormone therapy
20. P2.14-04 Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study.
21. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy.
22. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial
23. PT015 - Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: A systematic review by the Testicular Cancer Guidelines Panel
24. The impact of Mesenchymal Stem Cells and their secretome as a treatment for gliomas.
25. Progress in Identifying High Nature Value Montados: Impacts of Grazing on Hardwood Rangeland Biodiversity.
26. EP08.02-131 Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program.
27. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC.
28. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study.
29. Macrophage cell membrane infused biomimetic liposomes for glioblastoma targeted therapy.
30. P022 - Laparoscopic salvage lymph node dissection in biochemical recurrence after radical prostatectomy and salvage radiotherapy. Feasibility, security, and results
31. PP01.17 Sotorasib in Advanced KRAS p.G12C–Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP).
32. 697 Predictive model of postoperative complications after supine percutaneous nephrolithotomy
33. OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy.
34. Size-dependent reinforcement of composite rubbers.
35. EP08.01-049 Unscheduled Hospitalizations in Patients With Thoracic Tumors in the Era of Immunotherapy.
36. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial.
37. 485 The prognostic effect of a repeat transurethral resection prior to neoadjuvant chemotherapy for urothelial carcinoma of the bladder
38. Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial.
39. New insights in β-tubulin sequence analysis in non-small cell lung cancer
40. MA14.02 RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study.
41. OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study.
42. Small bowell perforation and mesentery injury after an unusual blunt abdominal trauma–Case report.
43. Prior day's intake has macronutrient-specific delayed negative feedback effects on the spontaneous food intake of free-living humans.
44. PCN90 Economic IMPACT of the NSCLC Molecular Diagnosis in Spain: A Retrospective Analysis of Healthcare Resources Use and Associated Costs from the LUNG-One Study.
45. P1.09-09 Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients.
46. OA01.05 Phase II Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer- Nadim Study-SLCG.
47. P2.09-11 TMB Estimated with Targeted NGS in Early Stage Squamous Cell Carcinoma: Correlation with PD-L1 Expression and Lymphocyte Density.
48. 250 - Autofluorescence as a new biomarker to identify glioblastoma stem cells.
49. Adverse Events Costs Associated With Erlotinib Or Afatinib In Non-Small Cell Lung Cancer (Nsclc) Patients With Egfr Mutation-Positive Tumours.
50. PCN76 Cost-Effectiveness of Erlotinib as First-Line Maintenance Therapy for Advanced Non-Small-Cell Lung Carcinoma in Patients EGFR WT and Stable Disease After Four Cycles of Chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.